SciBase在美国启动自费模式，以使Nevisense测试更容易被患者接受-动脉网

SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients

CISION 等信源发布 2025-06-09 21:23



可切换为仅中文







STOCKHOLM

斯德哥尔摩

，

June 9, 2025

2025年6月9日

/PRNewswire/ --

SciBase Holding AB ('SciBase')

SciBase控股公司（“SciBase”）

(STO: SCIB)

（斯德哥尔摩证券交易所：SCIB）

，

a leading developer of augmented intelligence-based solutions for skin disorders, today announced the launch of the Nevisense Self-Pay Program in the US, a new initiative designed to improve patient access to the Nevisense test outside of traditional insurance coverage. The program is being implemented at dermatology practices enrolled in the self-pay solution and addresses increasing demand for the Nevisense test directly from patients and dermatologists.

一家基于增强智能开发皮肤疾病解决方案的领先公司，今天宣布在美国推出Nevisense自费计划，这是一项旨在改善患者在传统保险范围之外获取Nevisense测试的新举措。该计划正在参与自费解决方案的皮肤病诊所实施，并满足了患者和皮肤科医生对Nevisense测试日益增长的需求。

SciBase has enrolled several practices located throughout the US and plans to further expand the program to meet clinician and patient needs..

SciBase已经注册了位于美国各地的多家医疗机构，并计划进一步扩展该项目，以满足临床医生和患者的需求。

Driven by evolving standards of care and a growing clinical emphasis on early detection, dermatologists have shown a strong interest in making Nevisense available to patients irrespective of payer status. The new Self-Pay Program empowers clinicians to incorporate Nevisense into their diagnostic workflow sooner - ensuring that patients at risk for melanoma are not left waiting due to insurance limitations..

随着护理标准的不断演变和临床对早期检测的日益重视，皮肤科医生表现出强烈兴趣，希望无论患者的支付能力如何，都能让他们获得Nevisense检测。新的自费付费计划使临床医生能够更早地将Nevisense纳入他们的诊断流程中，确保那些有黑色素瘤风险的患者不会因保险限制而延误检测。

We continue to work diligently to expand payer coverage and reimbursement, but we also recognize the urgent need for early detection

我们继续努力扩大支付者的覆盖范围和报销，但我们也认识到早期检测的迫切需求

,' said

，' 说

Pia Renaudin

皮亚·勒诺丹

, CEO of SciBase. '

SciBase首席执行官。'

The Self-Pay Program is a critical step in making Nevisense more widely available to clinicians and patients who value early, accurate melanoma detection at the point of care

自费项目是让Nevisense更广泛地提供给重视在护理点早期、准确检测黑色素瘤的临床医生和患者的关键一步。

As melanoma rates continue to rise globally, the importance of early diagnosis has never been greater. Nevisense offers a point-of-care solution that enhances clinical decision-making and supports earlier detection - ultimately improving outcomes and reducing the long-term burden on healthcare systems..

随着黑色素瘤发病率在全球范围内持续上升，早期诊断的重要性前所未有。Nevisense 提供了一种即时诊疗解决方案，有助于增强临床决策能力并支持更早发现病变，最终改善治疗效果并减轻对医疗系统的长期负担。

With the introduction of the Self-Pay Program, SciBase is reinforcing its commitment to innovation, access, and sustainable healthcare. The initiative enables more patients to benefit from Nevisense while helping clinicians deliver exceptional care through early melanoma detection.

通过引入自费项目，SciBase进一步强化了其对创新、可及性和可持续医疗的承诺。该举措使更多患者能够从Nevisense中受益，同时帮助临床医生通过早期黑色素瘤检测提供卓越的医疗服务。

For additional information, please contact:

请联系以获取更多信息：

Pia Renaudin

皮亚·勒诺丹

, CEO, tel. +46732069802, e-mail:

，首席执行官，电话：+46732069802，电子邮件：

pia.renaudin@scibase.com

皮亚·勒诺丹@赛斯贝斯.康

Certified Advisor (CA):

认证顾问 (CA):

DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail:

DNB Carnegie 投资银行 AB（公众有限公司）电话：+46 (0)73 856 42 65 电子邮件：

certifiedadviser@carnegie.se

认证顾问@carnegie.se

About SciBase

关于SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management..

SciBase是一家全球医疗技术公司，专注于皮肤病学的早期检测和预防。SciBase开发、制造并商业化Nevisense，这是一款独特的即时诊疗平台，结合人工智能和先进的EIS技术以提高诊断准确性，确保主动的皮肤健康管理。

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

我们的承诺是尽量减少患者痛苦，让临床医生能够通过及时的检测和干预改善和挽救生命，并降低医疗成本。

Built on more than 20 years of research at

基于二十多年的研究

Karolinska Institute

卡罗林斯卡研究所

在

Stockholm, Sweden

瑞典，斯德哥尔摩

, SciBase is a leader in dermatological advancements.

，SciBase是皮肤病学进步的领导者。

The company has been on the Nasdaq First North Growth Market exchange since

该公司自以下时间起已在纳斯达克第一北方成长市场交易所上市：